Biogen Inc. (BIIB) Stake Lowered by IBM Retirement Fund

Henrietta Strickland
July 1, 2017

Deutsche Bank has "Buy" rating and $31 target. The firm has "Buy" rating given on Monday, July 27 by Argus Research. The rating was downgraded by Robert W. Baird to "Neutral" on Monday, July 27. The company was initiated on Tuesday, February 23 by Buckingham Research. On Friday, December 4 the stock rating was maintained by Wells Fargo with "Outperform". (PX) stake by 18.7% reported in 2016Q4 SEC filing. Philadelphia Trust Company sold 2,500 shares as Biogen Inc (BIIB)'s stock declined 13.45%. (NASDAQ:ISBC) to report $0.16 EPS on July, 26.They anticipate $0.01 EPS change or 6.67% from last quarter's $0.15 EPS.

Shares of Biogen Inc. The stock rose 2.05% or $1.26 reaching $62.84. About 41,965 shares traded.

Biogen (NASDAQ BIIB) opened at 271.25 on Monday. It has underperformed by 11.76% the S&P500.

Wolverine Asset Ltd Liability Corporation has invested 0.01% in Biogen Inc (NASDAQ:BIIB). Buy rating has been given by 0 analysts to the company stock whereas 3 given UNDERPERFORM rating to stock and 12 given HOLD rating.

06/14/2017 - Biogen Idec Inc. had its " rating reiterated by analysts at Morgan Stanley. Cowen & Co maintained Biogen Inc (NASDAQ:BIIB) on Tuesday, August 25 with "Buy" rating. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. More interesting news about Biogen Inc (NASDAQ:BIIB) were released by: and their article: "The "Best Balance Sheets" Portfolio: Biogen And Bioverativ" published on June 05, 2017 as well as's news article titled: "Alexion hires Biogen executive to serve as its CFO" with publication date: June 13, 2017. Imperial Capital initiated Controladora Vuela Co Avcn SA CV (NYSE:VLRS) on Thursday, June 29 with "Outperform" rating. (NYSE:TSN) rating on Tuesday, November 24. Twelve analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. As per Friday, March 11, the company rating was maintained by Robert W. Baird. The firm has "Outperform" rating by RBC Capital Markets given on Tuesday, November 24. The firm earned "Hold" rating on Wednesday, October 5 by Jefferies. They issued a "buy" rating and a $315.00 target price for the company.

Investors sentiment decreased to 0.92 in 2016 Q4. "(BIIB) Stake Lowered by IBM Retirement Fund" was originally reported by Transcript Daily and is owned by of Transcript Daily. The correct version of this report can be viewed at First Heartland Consultants reported 0.07% stake. Company insiders own 0.32% of the company's stock. It also reduced Ishares Tr (HYG) stake by 334,250 shares and now owns 455,910 shares. Adirondack Company invested 0.03% in Biogen Inc (NASDAQ:BIIB). Cornerstone Advisors owns 1,194 shares or 0.28% of their USA portfolio. Exchange Mgmt Inc holds 7,522 shares. 7,815 were reported by Tudor Corp Et Al. Stratos Wealth Ptnrs invested in 7,911 shares or 0.14% of the stock. Commerce Bankshares holds 11,583 shares or 0.01% of its portfolio. Letko Brosseau Associates reported 218,341 shares. Hudock Capital Group Incorporated Limited owns 0.02% invested in Biogen Inc (NASDAQ:BIIB) for 100 shares. The Japan-based Hikari Pwr Ltd has invested 1.01% in Biogen Inc (NASDAQ:BIIB). Pensionfund Dsm Netherlands reported 0.64% of its portfolio in Biogen Inc (NASDAQ:BIIB).

Since January 1, 0001, it had 6 insider buys, and 0 insider sales for $5.76 million activity. 1,333 shares valued at $380,425 were bought by Vounatsos Michel on Monday, February 27. Another trade for 9,891 shares valued at $2.88 million was made by Clancy Paul J on Monday, March 13. Shares for $282,238 were sold by Sandrock Alfred. 1,005 were accumulated by Davis R M. Eqis Capital Management has 0.08% invested in Biogen Inc (NASDAQ:BIIB).

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, April 25th. The institutional investor held 15.58M shares of the biological products (no diagnostic substances) company at the end of 2016Q4, valued at $4.42B, down from 15.69 million at the end of the previous reported quarter. During the same quarter previous year, the firm posted $4.79 EPS.

Investors sentiment increased to 1.02 in 2016 Q4. Its down 0.12, from 1.03 in 2016Q3. Alphabet Inc was reduced too. 78 funds opened positions while 162 raised stakes. Cullen Frost Bankers Inc stated it has 16,851 shares or 0.16% of all its holdings. Cramer Rosenthal Mcglynn Ltd Liability Co holds 0.2% or 177,975 shares. (NYSE:TSN). Zacks has invested 0.02% in Tyson Foods, Inc. (NASDAQ:DLTR) for 904 shares. Winch Advisory Svcs Lc holds 0.01% or 30 shares in its portfolio. Hutchin Hill Lp invested 0.05% in Dollar Tree, Inc. Loomis Sayles Limited Partnership, Massachusetts-based fund reported 250 shares. Peak6 Investments Limited Partnership reported 32,842 shares stake. The Illinois-based Oakbrook Invests Ltd Liability has invested 0.25% in Biogen Inc (NASDAQ:BIIB). (NASDAQ:DLTR) or 575,000 shares. Entellus Medical Inc (NASDAQ:ENTL) has declined 17.59% since June 30, 2016 and is downtrending. It has underperformed by 50.49% the S&P500. Its down 2.12, from 3.67 in 2016Q3. PANGIA ROBERT W sold $1.61M worth of stock. Renaissance Technologies LLC now owns 707,495 shares of the biotechnology company's stock valued at $200,631,000 after buying an additional 469,234 shares in the last quarter. The company has a market cap of $58.26 billion, a price-to-earnings ratio of 17.20 and a beta of 0.83. As of January 28, 2017, the Company operated 14,334 stores in 48 states and the District of Columbia, and five Canadian provinces.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article